Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion

Mauri,Francesco   A.; Pinato,David   J.; Trivedi,Pritesh; Sharma,Rohini; Shiner,Robert  J.

doi:10.3892/or.2012.1818

Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion

Authors:
- Francesco A. Mauri
- David J. Pinato
- Pritesh Trivedi
- Rohini Sharma
- Robert J. Shiner
View Affiliations

Affiliations: Department of Histopathology, Imperial College London, Hammersmith Campus, London, UK, Division of Experimental Medicine, Imperial College London, Hammersmith Campus, London, UK, National Heart and Lung Institute, Department of Respiratory Medicine, Hammersmith Hospital, London, UK
Published online on: May 17, 2012 https://doi.org/10.3892/or.2012.1818
Pages: 647-653

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic diffusion is a major adverse prognostic determinant in lung cancer, that is ultimately responsible for significant morbidity, organ failure and death. Chemokine signaling pathways are known to guide site-specific metastatic spread in solid tumours. However, little is known about the contribution of CX3CR1 in the systemic dissemination of lung cancer. Syngeneic primary lung cancer/metastasis tissue microarray slides were constructed using 98 post-mortem specimens taken from patients with untreated lung cancer and immunostained for CX3CR1. Clinicopathological correlation between CX3CR1 expression and patient demographics, tumour histology, stage and pattern of metastatic spread was performed using χ2 test. CX3CR1 immunopositivity was significantly higher in non-small cell lung cancer (NSCLC) compared to small cell (SCLC) primary (p<0.001) and secondary tumours (p<0.001), with >75% of the metastatic sites staining positively in NSCLC. CX3CR1 positivity was significantly associated with stage and number of metastatic sites (p=0.03). At patients' death CX3CR1-negative lung adenocarcinomas were more likely to have spread to the brain and the liver (p=0.01). CX3CR1 is upregulated in NSCLC metastatic disease and its expression in primary lung tumours relates inversely to organotropic spread of cancer cells to the brain and the liver.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Cersosimo RJ: Lung cancer: a review. Am J Health Syst Pharm. 59:611–642. 2002.PubMed/NCBI
3	Fry WA, Phillips JL and Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 86:1867–1876. 1999.PubMed/NCBI
4	Sawaya R: Considerations in the diagnosis and management of brain metastases. Oncology (Williston Park). 15:1144–1165. 2001.PubMed/NCBI
5	Langley RR and Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 28:297–321. 2007. View Article : Google Scholar : PubMed/NCBI
6	Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003.
7	Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM and Keane MP: CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci. 1028:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
8	Singh S, Sadanandam A and Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 26:453–467. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
10	Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
11	Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 105:186–189. 2003. View Article : Google Scholar : PubMed/NCBI
12	Marchesi F, Piemonti L, Fedele G, et al: The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68:9060–9069. 2008. View Article : Google Scholar : PubMed/NCBI
13	Andre F, Cabioglu N, Assi H, et al: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 17:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
14	Marshall HM, Leong SC, Bowman RV, Yang IA and Fong KM: The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. Respirology. 17:247–260. 2012. View Article : Google Scholar : PubMed/NCBI
15	Dhillon T, Mauri FA, Bellezza G, et al: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 5:314–319. 2010. View Article : Google Scholar : PubMed/NCBI
16	Shi SR, Key ME and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 39:741–748. 1991. View Article : Google Scholar
17	Andreasson U, Ek S, Merz H, et al: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett. 259:138–145. 2008. View Article : Google Scholar : PubMed/NCBI
18	White ES, Flaherty KR, Carskadon S, et al: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 9:853–860. 2003.PubMed/NCBI
19	Burger M, Glodek A, Hartmann T, et al: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 22:8093–8101. 2003. View Article : Google Scholar : PubMed/NCBI
20	Hartmann TN, Burger JA, Glodek A, Fujii N and Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
21	Raynaud CM, Mercier O, Dartevelle P, et al: Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. Clin Lung Cancer. 11:187–191. 2010. View Article : Google Scholar : PubMed/NCBI
22	Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar
23	Kim M, Rooper L, Xie J, Kajdacsy-Balla AA and Barbolina MV: Fractalkine receptor CX3CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res. 10:11–24. 2012. View Article : Google Scholar
24	Matsubara T, Ono T, Yamanoi A, Tachibana M and Nagasue N: Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol. 95:241–249. 2007. View Article : Google Scholar
25	Jubb AM, Cesario A, Ferguson M, et al: Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer. 104:1877–1881. 2011. View Article : Google Scholar : PubMed/NCBI
26	Baird AM, Gray SG and O’Byrne KJ: Epigenetics underpinning the regulation of the CXC (ELR⁺) chemokines in non-small cell lung cancer. PLoS One. 6:e145932011. View Article : Google Scholar : PubMed/NCBI
27	Mizuno T, Kawanokuchi J, Numata K and Suzumura A: Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 979:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hurst LA, Bunning RA, Couraud PO, et al: Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol. 210:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
29	Imaizumi T, Yoshida H and Satoh K: Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb. 11:15–21. 2004. View Article : Google Scholar : PubMed/NCBI
30	Nevo I, Sagi-Assif O, Meshel T, et al: The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett. 273:127–139. 2009. View Article : Google Scholar : PubMed/NCBI
31	Yamazaki K, Sugio K, Yamanaka T, et al: Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. Anticancer Res. 30:1311–1315. 2010.
32	Lee SJ, Namkoong S, Kim YM, et al: Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol. 291:H2836–H2846. 2006. View Article : Google Scholar : PubMed/NCBI
33	Oh Y, Taylor S, Bekele BN, et al: Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 115:2930–2938. 2009. View Article : Google Scholar : PubMed/NCBI
34	Mamon HJ, Yeap BY, Janne PA, et al: High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 23:1530–1537. 2005. View Article : Google Scholar : PubMed/NCBI
35	Chen AM, Jahan TM, Jablons DM, Garcia J and Larson DA: Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 109:1668–1675. 2007. View Article : Google Scholar
36	Simon GR and Turrisi A: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132:S324–S339. 2007. View Article : Google Scholar
37	Besse B, Massard C, Haddad V, et al: ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann Oncol. 22:575–581. 2011. View Article : Google Scholar : PubMed/NCBI
38	D’Haese JG, Demir IE, Friess H and Ceyhan GO: Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets. 14:207–219. 2010.PubMed/NCBI